GENERAL INFORMATION
| HOME | ABOUT US | ARCHIVE | AIMS AND SCOP | AUTHORS | REVIEW | SUMIBMIT MANUSCRIPT | EDITORIAL BOARED | PUBLICATION FEE |
| HOME || ABOUT US || ARCHIVES || AIMS AND SCOP || AUTHORS || REVIEW|| SUBMIT MANUSCRIPT || EDITORIAL BOARD |
| Info-AJIRAS-® Journal ISSN 2429-5396 (Online) / Reference CIF/15/0289M |
American Journal of Innovative Research & Applied Sciences
|
American Journal of innovative
Research & Applied Sciences
Research & Applied Sciences
ISSN 2429-5396 (Online)
OCLC Number: 920041286
OCLC Number: 920041286
| ISSN: 2429-5396 (e) | https://www.american-jiras.com | |
| Web Site Form: v 0.1.05 | JF 22 Cours, Wellington le Clairval, Lillebonne | France |
| Web Site Form: v 0.1.05 | JF 22 Cours, Wellington le Clairval, Lillebonne | France |
Abstarct7-December-2023
| JUNE | VOLUME 22 | ISSUE N° 6 | 2026 |
| ARTICLES | Am. J. innov. res. appl. sci. Volume 22, Issue - 6 (Pages 10-16 (June, 2026)
| ARTICLES | Am. J. innov. res. appl. sci. Volume 22, Issue - 6 (Pages 10-16 (June, 2026)
Authors Contact
*Correspondant author and authors Copyright © 2026:
|Basma ZAHER 1*| Soukaina OUJDAD 1 | and | Lamia KISSI 1|
Affiliation.
1. Hassan 1 I university | dental medicine faculty of Casablanca | department of oral medicine
and oral surgery | Morocco |
This article is made freely available as part of this journal's Open Access:
| [ Doi : https://doi.org/10.5281/zenodo.20688316 ] | ID: [Basma-Ref2-6-22ajiras050626 ] |
RESUME
Background: Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a severe iatrogenic complication of antiresorptive therapy, most frequently observed in oncological patients receiving high-dose intravenous bisphosphonates. Despite growing clinical recognition since its first description in 2003, the condition remains difficult to manage, with no universally accepted therapeutic standard and a pathophysiology that is still incompletely understood. Case presentation: We report the case of a 29-year-old woman with acute myeloid leukemia, treated with intensive chemotherapy and intravenous bisphosphonates for four months, who presented with recurrent upper genian cellulitis, bone denudation, and loss of her maxillary dental bridge. Intraoral examination revealed extensive exposed necrotic bone extending from tooth 13 to tooth 26, with marked mucosal inflammation, purulent deposits, and spontaneous loss of teeth 11, 12, 21, and 25. Panoramic radiography demonstrated empty alveolar sockets with absence of bone healing, and cone-beam computed tomography (CBCT) confirmed complete sequestration of the dentoalveolar block 13–25, with a radiolucent line located 3 to 5 mm from residual apices. Clinical staging was consistent with Stage III BRONJ according to the 2022 American Association of Oral and Maxillofacial Surgeons (AAOMS) criteria. Initial management consisted of antiseptic irrigations, antibiotic therapy, and analgesics. The patient died three weeks after the consultation. Interpretation: This case illustrates the fulminant potential of BRONJ in young immunocompromised oncological patients, where the combination of high-potency intravenous bisphosphonates and chemotherapy-induced immunosuppression dramatically accelerates disease onset and progression. CBCT proved essential for precise three-dimensional delineation of the sequestrated bone block, beyond what panoramic radiography could provide. This observation reinforces the absolute necessity of systematic pre-therapeutic oral assessment and elimination of infectious dental foci prior to initiating any intravenous antiresorptive regimen, alongside close interdisciplinary collaboration between oncologists, hematologists, oral surgeons, and dental practitioners. For this severe and potentially life-threatening complication, prevention remains immeasurably more effective than cure..
Background: Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a severe iatrogenic complication of antiresorptive therapy, most frequently observed in oncological patients receiving high-dose intravenous bisphosphonates. Despite growing clinical recognition since its first description in 2003, the condition remains difficult to manage, with no universally accepted therapeutic standard and a pathophysiology that is still incompletely understood. Case presentation: We report the case of a 29-year-old woman with acute myeloid leukemia, treated with intensive chemotherapy and intravenous bisphosphonates for four months, who presented with recurrent upper genian cellulitis, bone denudation, and loss of her maxillary dental bridge. Intraoral examination revealed extensive exposed necrotic bone extending from tooth 13 to tooth 26, with marked mucosal inflammation, purulent deposits, and spontaneous loss of teeth 11, 12, 21, and 25. Panoramic radiography demonstrated empty alveolar sockets with absence of bone healing, and cone-beam computed tomography (CBCT) confirmed complete sequestration of the dentoalveolar block 13–25, with a radiolucent line located 3 to 5 mm from residual apices. Clinical staging was consistent with Stage III BRONJ according to the 2022 American Association of Oral and Maxillofacial Surgeons (AAOMS) criteria. Initial management consisted of antiseptic irrigations, antibiotic therapy, and analgesics. The patient died three weeks after the consultation. Interpretation: This case illustrates the fulminant potential of BRONJ in young immunocompromised oncological patients, where the combination of high-potency intravenous bisphosphonates and chemotherapy-induced immunosuppression dramatically accelerates disease onset and progression. CBCT proved essential for precise three-dimensional delineation of the sequestrated bone block, beyond what panoramic radiography could provide. This observation reinforces the absolute necessity of systematic pre-therapeutic oral assessment and elimination of infectious dental foci prior to initiating any intravenous antiresorptive regimen, alongside close interdisciplinary collaboration between oncologists, hematologists, oral surgeons, and dental practitioners. For this severe and potentially life-threatening complication, prevention remains immeasurably more effective than cure..
ARTICLE 2 PDF
Friday, September 19, 2025
BISPHOSPHONATE-RELATED OSTEONECROSIS OF THE MAXILLARY: CASE REPORTSend Comments
| Basma ZAHER 1*| Soukaina OUJDAD 1 | and | Lamia KISSI 1|. Am. J. innov. res. appl. sci. 2026; 22(6):10-16
| PDF FULL TEXT | | XML FILE | | HTML FILE | | [ Doi : https://doi.org/10.5281/zenodo.20688316 ] |
| PDF FULL TEXT | | XML FILE | | HTML FILE | | [ Doi : https://doi.org/10.5281/zenodo.20688316 ] |